文献速递前列腺癌

是否应将Gleason分级分组1前列腺癌视为「阴性穿刺芯」?一项国际多中心分析

Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
PubMed 文献 · Urology · 2019-11-06

该多中心回顾性研究纳入7718例根治性前列腺切除术前接受穿刺的患者,比较原始与选择性(将GG1穿刺芯视为阴性)列线图对病理结局的预测。结果显示在GG2且伴GG1穿刺芯的患者中,选择性列线图对淋巴结侵犯、包膜外侵犯和器官局限疾病的预测更接近根治标本病理,但对精囊侵犯无改善。

要点

  • 将GG1穿刺芯视为阴性可改善GG2患者术前列线图对LNI、ECE和OCD的预测。
  • 该调整对SVI预测无改善,且在GG3-5患者中结果一致。
  • 对GG1-2患者的管理影响最大,部分患者LNI风险跨越2%或5%阈值。

核心结论

  • 将GG1前列腺癌穿刺芯从术前列线图中排除能更好预测根治性前列腺切除后的病理结局,并可能更真实反映肿瘤负荷。

研究设计与样本

  • 多机构回顾性病历审查,纳入2008至2018年间接受根治性前列腺切除且行前列腺穿刺的7718例患者。

主要发现

  • 在GG2且伴GG1穿刺芯患者中,MSKCC列线图LNI预测值原始4.97% vs 选择性3.50%,Briganti列线图原始4.81% vs 选择性2.49%,根治病理LNI为2.46%。
  • 同组患者OCD预测MSKCC原始40.91% vs 选择性48.44%,根治病理OCD为68.46%;ECE预测原始57.87% vs 选择性50.38%,根治病理ECE为30.41%。
  • SVI预测MSKCC原始5.42% vs 选择性3.34%,根治病理SVI为5.62%,未见改善。
  • GG3-5疾病中结果与GG2一致。
  • GG1患者管理显著影响(Δ2)为26.3%-31.0%,Δ5为1.5%-5.2%;GG2患者Δ2为3.4%-22.2%,Δ5为12.3%-13.6%。

关键数值与推荐

  • 临床显著管理影响定义为LNI风险变化跨越2%或5%阈值(Δ2/Δ5)。
  • 列线图迭代包括原始(所有穿刺芯数据)和选择性(GG1穿刺芯视为阴性)。

临床怎么用

  • 在术前咨询和决策中,可考虑将GG1穿刺芯视为阴性以更准确评估淋巴结侵犯和包膜外侵犯风险。

局限性

  • 回顾性研究设计可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of excluding Gleason Grade Group 1 (GG1) prostate cancer (CaP) cores from current pre-radical prostatectomy (RP) nomograms. METHODS: Multi-institutional retrospective chart review was performed on all RP patients with prostate biopsy between 2008 and 2018. Patients were individually assessed using the Memorial Sloan Kettering Cancer Center (MSKCC) and Briganti nomograms using the following iterations: (1) Original [ORIG] - all available core data and (2) Selective [SEL] - GG1 cores considered negative. Nomogram outcomes - lymph node invasion (LNI), extracapsular extension (ECE), organ-confined disease (OCD), seminal vesicle invasion (SVI), were compared across iterations and stratified based on biopsy GG. Clinically significant impact on management (CSIM) was defined as change in LNI risk above or below 2% or 5% (Δ2/Δ5). Nomogram outcomes were validated with RP pathology. RESULTS: 7718 men met inclusion criteria. In men with GG2 who also had GG1 cores, SEL better predicted LNI (MSKCC - ORIG 4.97% vs SEL 3.50%; Briganti - ORIG 4.81% vs SEL 2.49%, RP outcome 2.46%), OCD (MSKCC - ORIG 40.91% vs SEL 48.44%, RP outcome: 68.46%) and ECE (MSKCC - ORIG 57.87% vs SEL 50.38%, RP outcome: 30.41%), but not SVI (MSKCC - ORIG 5.42% vs SEL 3.34%, RP outcome: 5.62%). This was also consistent in patients with GG3-5 disease. The greatest CSIM was on GG1-2 CaP; Δ2 and Δ5 in GG1 patients was 26.3%-31.0% and 1.5%-5.2%, respectively, and Δ2 and Δ5 in GG2 patients was 3.4%-22.2% and 12.3%-13.6%, respectively. CONCLUSION: Excluding GG1 CaP cores from pre-RP nomograms better predicts final RP pathologic outcomes. More importantly, this may better reflect extent of true cancer burden.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Leong JY, Herrera-Caceres JO, Goldberg H, et al. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis. Urology. 2019. PMID: 31705947. doi:10.1016/j.urology.2019.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。